CHENNAI: Lupin has received the Drug Controller General of India (DCGI) approval to launch India’s first selective and specific sinus node of channel inhibitor; IVABRAD (Ivabradine) which is now available in 5 mg and 7.5 mg tablets. IVABRAD comes from Pinnacle, Lupin’s marketing division for specialty drugs in India, according to a release.